# A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

> **NCT05928585** · PHASE1 · COMPLETED · sponsor: **HI-Bio, A Biogen Company** · enrollment: 30 (actual)

## Conditions studied

- Immune System Diseases
- Autoimmunity

## Interventions

- **DRUG:** HIB210
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05928585
- **Lead sponsor:** HI-Bio, A Biogen Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-06
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928585, "A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05928585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*